Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).
Thomas S. Vedvick
Advertisement
Thomas S. Vedvick is the director of process sciences at the Infections Disease Research Institute, Seattle, WA
Articles by Thomas S. Vedvick
The HMS174 strain, in the absence or presence of excess phosphate, can metabolize acetate efficiently.
Advertisement
Latest Updated Articles
The Effect of Limiting Phosphate Using the HMS174 Cell LinePublished: July 1st 2010 | Updated:
Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNsPublished: October 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
